NCT00272311

Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome

A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 70 (actual)
• Sponsor: Florida Atlantic University · Academic / Other
• Sex: All
• Age: 40 Years – 80 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to test higher versus lower doses of aspirin on markers of atherosclerosis in patients at risk of a first heart attack.

Detailed description

Aspirin reduces risks of heart attacks, strokes, and deaths from cardiovascular causes in patients who have survived a prior event as well as during an acute heart attack. Aspirin also prevents a first heart attack. Low dose aspirin is sufficient to achieve complete inhibition of platelet aggregability, or stickiness, and this is the mechanism whereby aspirin prevents formation of blood clots. Our research is designed to explore whether higher doses of aspirin provide additional benefits on markers of atherosclerosis.

Conditions

• Cardiovascular Diseases
• Metabolic Syndrome X
• Atherosclerosis

Interventions

Type	Name	Description
DRUG	Aspirin	Dosage

Timeline

• Start date: 2006-10-01
• Primary completion: 2009-01-01
• Completion: 2009-01-01
• First posted: 2006-01-05
• Last updated: 2019-02-27
• Results posted: 2012-06-19

Locations

1 site across 1 country: United States